论文部分内容阅读
希美纳(注射用甘氨双唑钠)是目前在临床唯一正式应用的放疗增敏剂,国家一类新药; 希美纳适用于进行放疗的鼻咽癌、食管癌、肺癌、宫颈癌等实体瘤患者; 希美纳针对肿瘤乏氧细胞,对实体瘤有明显的放疗增敏作用, 尤其能提高肿瘤的完全缓解率并能明显提高肿瘤放疗后1、2、3年长期生存率; 希美纳具卓越的安全性: 希美纳获得2005年国家科技发明二等奖。
Simena (sodium glycididazole for injection) is currently the only clinically-applied radiosensitizer in the country. It is a new class of drug in the country; Simena is suitable for solid tumors such as nasopharyngeal cancer, esophageal cancer, lung cancer, and cervical cancer for radiotherapy. Patients; Simena targeted tumor hypoxic cells and has a significant radiosensitization effect on solid tumors, in particular, can improve the complete remission rate of the tumor and can significantly improve the long-term survival rate of 1, 2 and 3 years after radiotherapy; Siminar has excellent Security: Simeon received the second prize for national science and technology invention in 2005.